Scilex Holding Company Net Income (Loss) Attributable to Redeemable Noncontrolling Interest
Scilex Holding Company (SCLX) reported Net Income (Loss) Attributable to Redeemable Noncontrolling Interest of $1.33 million for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-07-23.
Discontinued › Income Statement
us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest · last filed 2021-07-23
- Scilex Holding Company net income (loss) attributable to redeemable noncontrolling interest for the quarter ending 2021-03-31 was $1.33M.
| Period end | Net Income (Loss) Attributable to Redeemable Noncontrolling Interest 1 month | Net Income (Loss) Attributable to Redeemable Noncontrolling Interest 3 month |
|---|---|---|
| 2021-03-31 | $1.33M 10-Q · filed 2021-07-23 | |
| 2020-03-31 | -$5.00K 10-Q · filed 2021-07-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |